Form 8-K - Current report:
SEC Accession No. 0001829126-26-004744
Filing Date
2026-05-07
Accepted
2026-05-07 16:07:42
Documents
13
Period of Report
2026-05-07
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kalabio_8k.htm   iXBRL 8-K 44573
2 EXHIBIT 3.1 kalabio_ex3-1.htm EX-3.1 15549
3 EXHIBIT 99.1 kalabio_ex99-1.htm EX-99.1 15421
  Complete submission text file 0001829126-26-004744.txt   250200

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE kala-20260507.xsd EX-101.SCH 2990
5 XBRL LABEL FILE kala-20260507_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE kala-20260507_pre.xml EX-101.PRE 22342
16 EXTRACTED XBRL INSTANCE DOCUMENT kalabio_8k_htm.xml XML 3212
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 26953200
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)